Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Daniel M. F. Claassens"'
Autor:
Jaouad Azzahhafi, Thomas O. Bergmeijer, Wout W. A. van den Broek, Dean R. P. P. Chan Pin Yin, Senna Rayhi, Joyce Peper, Willem L. Bor, Daniel M. F. Claassens, Ron H. N. van Schaik, Jurriën M. ten Berg
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Aims: To determine the clinical efficacy, adverse events and side-effect dyspnea of CYP3A4*22 and CYP3A5 expressor status in ticagrelor treated patients.Methods and results: Ticagrelor treated patients from the POPular Genetics randomized controlled
Externí odkaz:
https://doaj.org/article/7ac9d46665ce483189d6a3185410c1aa
Autor:
Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Mohammed A. Al-Mansori, Rudaynah A. Alali, Rania M. Khalil, Khalid A. Al Faraidy, Cyril Cyrus, Mohammed M. Sulieman, Chittibabu Vatte, Daniel M. F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al-Ali
Publikováno v:
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodru
Externí odkaz:
https://doaj.org/article/75f51cb0afee4ee6b316c40a606decce
Autor:
Bakhtawar K. Mahmoodi, Niclas Eriksson, Stephanie Ross, Daniel M. F. Claassens, Folkert W. Asselbergs, Karina Meijer, Agneta Siegbahn, Stefan James, Guillaume Pare, Lars Wallentin, Jurriën M. ten Berg
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 17 (2021)
Background Whether factor V Leiden is associated with lower bleeding risk in patients with acute coronary syndromes using (dual) antiplatelet therapy has yet to be investigated. Methods and Results We pooled data from 3 randomized clinical trials, co
Externí odkaz:
https://doaj.org/article/fd44ded4e1244c748e43c5b5fe232661
Autor:
Jeehoon Kang, Konstantinos D Rizas, Kyung Woo Park, Jaewook Chung, Wout van den Broek, Daniel M F Claassens, Eun ho Choo, Dániel Aradi, Steffen Massberg, Doyeon Hwang, Jung-Kyu Han, Han-Mo Yang, Hyun-Jae Kang, Kiyuk Chang, Jur M ten Berg, Dirk Sibbing, Bon-Kwon Koo, Hyo-Soo Kim
Publikováno v:
European Heart Journal, 44(15), 1360-1370. Oxford University Press
Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the standard treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). De-escalation of the potent P2Y12 inhibtor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::708a28c9e991e0a8e434e04c7a8cbe6d
https://doi.org/10.1093/eurheartj/ehac829
https://doi.org/10.1093/eurheartj/ehac829
Autor:
Daniel M F, Claassens, Pim W M, van Dorst, Gerrit J A, Vos, Thomas O, Bergmeijer, Renicus S, Hermanides, Arnoud W J, van 't Hof, Pim, van der Harst, Emanuele, Barbato, Carmine, Morisco, Richard M, Tjon Joe Gin, Folkert W, Asselbergs, Arend, Mosterd, Jean-Paul R, Herrman, Willem J M, Dewilde, Maarten J, Postma, Vera H M, Deneer, Jurriën M, Ten Berg, Cornelis, Boersma
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 22(2)
The POPular Genetics trial demonstrated that a CYP2C19 genotype-guided P2YIn this analysis, we aimed to evaluate the cost effectiveness of a genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel.A 1-year decision tree
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2efc2d844eddc5888d596f5b53a046e3
https://pubmed.ncbi.nlm.nih.gov/34490590
https://pubmed.ncbi.nlm.nih.gov/34490590
Autor:
Anne H, Tavenier, Daniel M F, Claassens, Renicus S, Hermanides, Gerrit J A, Vos, Thomas O, Bergmeijer, Johannes C, Kelder, Vera H M, Deneer, Arnoud W J, van 't Hof, Jurriën M, Ten Berg
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES. 99(3)
Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI), although discussion about its clinical benefit is ongoing.GPI use
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b6cdc5ca2138cb0b5038b7e9751b9fea
https://pubmed.ncbi.nlm.nih.gov/34233065
https://pubmed.ncbi.nlm.nih.gov/34233065
Autor:
Abdullah M, Al-Rubaish, Fahad A, Al-Muhanna, Abdullah M, Alshehri, Abdulla A, Alsulaiman, Majed M, Alabdulali, Fahad, Alkhamis, Abdulallh S, Alamri, Rudaynah A, Alali, Mohammed S, Akhtar, Cyril, Cyrus, Daniel M F, Claassens, Folkert W, Asselbergs, Amein K, Al-Ali
Publikováno v:
Drug metabolism and personalized therapyReferences. 37(1)
To mitigate the incidence of recurrent stroke in patients, dual antiplatelet therapy comprising aspirin and clopidogrel is usually administered. Clopidogrel is a prodrug and its bioactivation is catalyzed by cytochrome P450 (CYP)2C19. The main object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5db5a27fb1d3b6f95f45f709ff026fd6
https://pubmed.ncbi.nlm.nih.gov/35385889
https://pubmed.ncbi.nlm.nih.gov/35385889
Autor:
Daniel M F, Claassens, Gerrit J A, Vos, Thomas O, Bergmeijer, Renicus S, Hermanides, Arnoud W J, van 't Hof, Pim, van der Harst, Emanuele, Barbato, Carmine, Morisco, Richard M, Tjon Joe Gin, Folkert W, Asselbergs, Arend, Mosterd, Jean-Paul R, Herrman, Willem J M, Dewilde, Paul W A, Janssen, Johannes C, Kelder, Maarten J, Postma, Anthonius, de Boer, Cornelis, Boersma, Vera H M, Deneer, Jurriën M, Ten Berg
Publikováno v:
The New England journal of medicine. 381(17)
It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2YWe conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7dfca0cfc958706907f69880eadf21ef
https://pubmed.ncbi.nlm.nih.gov/31644850
https://pubmed.ncbi.nlm.nih.gov/31644850